Preclinical studies have revealed beneficial effects of PPARβ/δ in the management of metabolic syndromes such as obesity, T2DM and NAFLD, or NASH [146]. This evidence concerns the gene PPARD and obesity due to melanocortin 4 receptor deficiency.